Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Show more...
首席执行官
Ms. Natalie C. Holles
员工
31
国家
US
ISIN
US88427A1079
上市
0 Comments
分享你的想法
FAQ
Third Harmonic Bio 今天的股价是多少?▼
THRD 当前价格为 $5.38 USD,在过去 24 小时内下跌了 -0.09%。在图表上更密切关注 Third Harmonic Bio 股票的表现。
Third Harmonic Bio 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Third Harmonic Bio 的股票以代码 THRD 进行交易。
Third Harmonic Bio 的股价在上涨吗?▼
THRD 股票较上周上涨 +0%,本月上涨 +0%,过去一年 Third Harmonic Bio 上涨 +54.6%。